Lucid Diagnostics announced a new contract with the U.S. Department of Veterans Affairs to supply its EsoGuard esophageal DNA test under the VA Federal Supply Schedule, giving VA hospitals nationwide access to the test at a price matching Medicare reimbursement.
The agreement will allow the test to be offered to more than nine million enrolled veterans, expanding Lucid’s potential market and providing a national procurement framework that could accelerate commercialization. The pricing alignment with Medicare rates removes a key barrier to adoption and positions Lucid to capture a share of the growing demand for non‑invasive esophageal cancer screening.
Lucid’s EsoGuard targets patients with chronic acid reflux, a high‑risk group for esophageal precancer. The VA contract is a milestone for the company, which has faced negative margins and a quarterly cash burn of about $10 million. The new revenue stream could help offset operating losses and support future clinical development, but Lucid’s valuation remains tied to Medicare reimbursement approval.
For PAVmed Inc., Lucid is the parent company’s largest equity holding. The contract is expected to increase Lucid’s test volumes and revenue, thereby enhancing the value of PAVmed’s stake and its management‑fee income. PAVmed’s Q3 2025 results showed a GAAP net loss of $6.3 million and a non‑GAAP adjusted loss of $0.4 million, underscoring the importance of the new contract for the holding company’s financial profile.
Shaun O'Neil, President and COO of Lucid Diagnostics, said the partnership “demonstrates the strength of the clinical evidence supporting EsoGuard and provides a pathway to broaden access for veterans.” He added that the company will work with the VA and other integrated health systems to integrate the test into standard clinical practice.
The announcement was met with strong investor interest, reflecting confidence in the potential scale of the VA contract and the broader market for early esophageal cancer detection.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.